2,2-Diethyl-buttersaeure-methylester | 10250-49-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,2-Diethyl-buttersaeure-methylester
• 英文别名: Triethylessigsaeure-methylester；2,2-Diethylbutansaeuremethylester；2,2-diethyl-butyric acid methyl ester；2,2-Diaethyl-buttersaeure-methylester；Methyl 2,2-diethylbutanoate
• CAS: 10250-49-4
• 化学式: C₉H₁₈O₂
• 分子量: 158.241
• InChiKey: IGTCPEIOLUENHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-Diethyl-buttersaeure-methylester 在 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 三乙基乙酸
  参考文献：
  名称：

  镍催化未活化 C(sp3)-H 键的位点选择性烷基化

  摘要：

  脂肪族酰胺的未活化 sp(3) CH 键的直接烷基化是通过镍催化在双齿导向基团的帮助下实现的。该反应有利于甲基的 CH 键而不是亚甲基的 CH 键，并且可以耐受各种官能团。此外，该反应表明，在环金属化步骤中，甲基的 sp(3) CH 键通过五元环中间体优先于芳烃的 sp(2) CH 键。

  DOI：

  10.1021/ja413131m
• 作为产物：
  描述：

  2,2-diethylbutanoyl chloride 、 sodium methylate 生成 2,2-Diethyl-buttersaeure-methylester
  参考文献：
  名称：

  Whitmore; Lewis, Journal of the American Chemical Society, 1942, vol. 64, p. 2965

  摘要：

  DOI：

文献信息

• Copper-Catalyzed Site-Selective Intramolecular Amidation of Unactivated C(sp³)H Bonds
  作者：Xuesong Wu、Yan Zhao、Guangwu Zhang、Haibo Ge

  DOI：10.1002/anie.201311263

  日期：2014.4.1

  of aliphatic amides, directed by a bidentate ligand, was developed using a copper‐catalyzed sp3 CH bond functionalization process. The reaction favors predominantly the CH bonds of β‐methyl groups over the unactivated methylene CH bonds. Moreover, a preference for activating sp3 CH bonds of β‐methyl groups, via a five‐membered ring intermediate, over the aromatic sp2 CH bonds was also observed in

  脂肪族酰胺的分子内酰胺化脱氢，由双齿配体定向，使用铜-催化的SP被开发3 Ç  H键官能化方法。该反应有利于主要的C  β甲基团与未活化的亚甲基] C H键 H键。此外，用于激活SP的偏好3 Ç  β甲基基团的H键，经由五元环中间，在所述芳族SP 2个ç  H键在环金属化步骤中也观察到。此外，SP 3个Ç 未活化二次属的H键3 Ç 通过使环碳原子优先于线性碳原子，可以使H键官能化。
• METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE
  申请人：API Corporation

  公开号：US20160083341A1

  公开（公告）日：2016-03-24

  According to the present invention, it becomes possible to perform a process for converting into an α-substituted cysteine represented by general formula (1) or a salt thereof at low cost and on an industrial scale by employing a process that is routed through a compound represented by general formula (3) to a compound represented by general formula (6). Particularly, by employing a process that is routed through a compound represented by general formula (7-2), it becomes possible to detach a tert-butyl protection group in a simple manner and to produce the compound represented by general formula (1) with high purity. Furthermore, by employing a process that is routed through tert-butylthiomethanol or a process that is routed through a compound represented by general formula (9), it becomes possible to produce a compound represented by general formula (2) without generating bischloromethylether that is an oncogenic substance. In the production of an α-substituted-D-cysteine or a salt thereof, it becomes possible to perform a process for converting the compound represented by general formula (2) into a compound represented by general formula (3S) in one step by allowing an enzyme or the like to act on the compound represented by general formula (2).

  根据本发明，通过采用经由一种化合物（通式（3）表示）到一种通式（6）表示的化合物的过程，可以以低成本和工业化规模进行将其转化为通式（1）表示的α-取代半胱氨酸或其盐的过程。特别是，通过采用经由一种通式（7-2）表示的化合物的过程，可以简单地去除叔丁基保护基，并以高纯度生产通式（1）表示的化合物。此外，通过采用经由叔丁基硫代甲醇或经由一种通式（9）表示的化合物的过程，可以生产通式（2）表示的化合物，而不产生致癌物质双氯甲醚。在生产α-取代-D-半胱氨酸或其盐时，可以通过允许酶或类似物作用于通式（2）表示的化合物，一步将其转化为通式（3S）表示的化合物。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson Howard John

  公开号：US20070219206A1

  公开（公告）日：2007-09-20

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一些化合物和含有这些化合物的制药组合物，这些化合物可以调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这种FLAP调节剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或病症。
• Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds
  申请人：Yuan Jun

  公开号：US20080267887A1

  公开（公告）日：2008-10-30

  Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R 2 , R 5 , E, Z 1 , Z 3 , Z 4 , and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.

  吡咯吡啶、吡咯嘧啶和相关杂环化合物的类似物的公式如下： 其中R，R2，R5，E，Z1，Z3，Z4和Ar在此定义。这些化合物是C5a受体的配体。本发明所述的优选吡咯吡啶、吡咯嘧啶和相关杂环化合物以高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物，并且涉及使用这些化合物治疗各种炎症、心血管和免疫系统疾病。此外，本发明提供了标记的吡咯吡啶、吡咯嘧啶和相关杂环化合物，这些化合物可用作C5a受体的定位探针。
• PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS
  申请人：Yuan Jun

  公开号：US20110118273A1

  公开（公告）日：2011-05-19

  Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R 2 , R 5 , E, Z 1 , Z 3 , Z 4 , and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.

  吡咯并吡啶、吡咯并嘧啶和相关杂环化合物的类似物的公式为：其中R、R2、R5、E、Z1、Z3、Z4和Ar的定义如下。这些化合物是C5a受体的配体。本发明所述的优选吡咯并吡啶、吡咯并嘧啶和相关杂环化合物以高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的吡咯并吡啶、吡咯并嘧啶和相关杂环化合物，这些化合物可用作C5a受体的定位探针。